Medivation's prostate drug earns European endorsement; New Haven Pharmaceuticals gets $2M boost;

@FierceBiotech: NIH stops HIV vaccine trial after immunizations fail. Story | Follow @FierceBiotech

@JohnCFierce: So EU doesn't like Pfizer's Xeljanz at all. That's a blow. More | Follow @JohnCFierce

@RyanMFierce: Industry Voices: Time to Take Fecal Transplantation Seriously. Article | Follow @RyanMFierce

> The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has endorsed approval of the prostate cancer drug Xtandi from Medivation ($MDVN) and Astellas Pharma. Release

> Horizon Technology has closed a $2 million venture loan facility with New Haven Pharmaceuticals. Release

> The new London Lung Cancer Alliance is aiming to conduct trials of personalized therapies for lung cancer with up to 3,000 patients a year. Story

Pharma News

@FiercePharma: Trending at FiercePharma.com: European regulators tag 100-plus drugs with 'black triangle. Article | Follow @FiercePharma

@EricPFierce: Ipsen warns of shortages of its orphan drug Increlex. Story | Follow @EricPFierce

> Docs call drugmakers 'profiteers' for costs of cancer meds. Story

> Pfizer appealing CHMP ruling on RA treatment Xeljanz. Report

> Humira carries AbbVie in its first quarter as standalone company. More

Medical Device News

@FierceMedDev: FDA wants more data on Insuline's pump. Article | Follow @FierceMedDev

@MarkHFierce: Now this is just cool: Carnegie Mellon U. folks are developing med devices you would swallow and partially digest. More | Follow @MarkHFierce

 @DamianFierce: A spike in restructuring costs slashed Covidien's profits, despite a revenue jump. Story | Follow @DamianFierce

> Insuline pump hits FDA obstacle. Item

> Life Tech shareholder sues over $13.6B Thermo buyout. Report

> VC giant NEA backs Topera in $25M Series C. Article

And Finally... Researchers found that being overweight or obese boosted the risk of developing prostate cancer by 57% in a study. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.